Cover
Cover - shares | 3 Months Ended | |
Mar. 31, 2023 | May 12, 2023 | |
Document Type | 10-Q | |
Amendment Flag | false | |
Document Quarterly Report | true | |
Document Transition Report | false | |
Document Period End Date | Mar. 31, 2023 | |
Document Fiscal Period Focus | Q1 | |
Document Fiscal Year Focus | 2023 | |
Current Fiscal Year End Date | --12-31 | |
Entity File Number | 001-39669 | |
Entity Registrant Name | COEPTIS THERAPEUTICS HOLDINGS, INC. | |
Entity Central Index Key | 0001759186 | |
Entity Tax Identification Number | 98-1465952 | |
Entity Incorporation, State or Country Code | DE | |
Entity Address, Address Line One | 105 Bradford Rd | |
Entity Address, Address Line Two | Suite 420 | |
Entity Address, City or Town | Wexford | |
Entity Address, State or Province | PA | |
Entity Address, Postal Zip Code | 15090 | |
City Area Code | 724 | |
Local Phone Number | 934-6467 | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Entity Small Business | true | |
Entity Emerging Growth Company | true | |
Elected Not To Use the Extended Transition Period | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 21,441,036 | |
Common Stock, par value $0.0001 per share | ||
Title of 12(b) Security | Common Stock, par value $0.0001 per share | |
Trading Symbol | COEP | |
Security Exchange Name | NASDAQ | |
Warrants, each whole warrant exercisable for one-half of one share of Common Stock for $11.50 per whole share | ||
Title of 12(b) Security | Warrants | |
Trading Symbol | COEPW | |
Security Exchange Name | NASDAQ |
CONDENSED CONSOLIDATED BALANCE
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) | Mar. 31, 2023 | Dec. 31, 2022 |
CURRENT ASSETS | ||
Cash | $ 2,106,832 | $ 3,791,302 |
Accounts receivable | 0 | 8,075 |
Prepaid assets, current portion | 169,148 | 142,356 |
TOTAL CURRENT ASSETS | 2,275,980 | 3,941,733 |
PROPERTY AND EQUIPMENT | ||
Furniture and fixtures | 25,237 | 25,237 |
Less: accumulated depreciation | 13,004 | 12,695 |
Furniture and fixtures, net | 12,233 | 12,542 |
OTHER ASSETS | ||
Prepaid insurance | 300,832 | 348,333 |
License right, net of accumulated amortization | 3,304,167 | 3,554,167 |
Right of use asset, net of accumulated amortization | 49,065 | 58,914 |
Total other assets | 3,654,064 | 3,961,414 |
TOTAL ASSETS | 5,942,277 | 7,915,689 |
CURRENT LIABILITIES | ||
Accounts payable | 242,453 | 99,021 |
Accrued expenses | 205,044 | 181,998 |
Notes payable, current portion | 1,500,000 | 1,500,000 |
Right of use liability, current portion | 31,561 | 41,618 |
TOTAL CURRENT LIABILITIES | 1,979,058 | 1,822,637 |
LONG TERM LIABILITIES | ||
Note payable | 150,000 | 150,000 |
Derivative liability warrants | 2,512,500 | 1,125,000 |
Right of use liability, non-current portion | 14,723 | 14,723 |
TOTAL LONG TERM LIABILITIES | 2,677,223 | 1,289,723 |
TOTAL LIABILITIES | 4,656,281 | 3,112,360 |
COMMITMENTS AND CONTINGENCIES (NOTE 6) | ||
STOCKHOLDERS' EQUITY (DEFICIT) | ||
Common stock, $0.0001 par value, 150,000,000 shares authorized, 20,941,036 shares issued and outstanding at March 31, 2023, and 19,566,839 shares outstanding at December 31, 2022 | 2,094 | 1,957 |
Additional paid-in capital | 74,171,869 | 70,541,095 |
Common stock subscribed | 720,000 | |
Accumulated deficit | (73,607,967) | (65,739,723) |
TOTAL STOCKHOLDERS' EQUITY | 1,285,996 | 4,803,329 |
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | 5,942,277 | 7,915,689 |
Series B Preferred Stock [Member] | ||
STOCKHOLDERS' EQUITY (DEFICIT) | ||
Preferred Stock, $0.0001 par value, 10,000,000 shares authorized, -0- and -0- shares issued and outstanding, respectively | $ 0 | $ 0 |
CONDENSED CONSOLIDATED BALANC_2
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares | Mar. 31, 2023 | Dec. 31, 2022 |
Statement of Financial Position [Abstract] | ||
Preferred stock, par value | $ 0.0001 | $ 0.0001 |
Preferred stock, shares authorized | 10,000,000 | 10,000,000 |
Preferred Stock, Shares Issued | 0 | 0 |
Preferred Stock, Shares Outstanding | 0 | 0 |
Common stock, par value | $ 0.0001 | $ 0.0001 |
Common stock, shares authorized | 150,000,000 | 150,000,000 |
Common stock, shares issued | 20,941,036 | 19,566,839 |
Common stock, shares outstanding | 20,941,036 | 19,566,839 |
CONDENSED CONSOLIDATED STATEMEN
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
Sales | ||
Total sales | $ 0 | $ 0 |
Cost of goods, including inventory obsolescence | 0 | 0 |
Gross profit | 0 | 0 |
COST OF OPERATIONS | ||
Research and development | 25,740 | 0 |
General and administrative expenses | 6,423,622 | 15,715,315 |
Total operating expenses | 6,449,362 | 15,715,315 |
LOSS FROM OPERATIONS | (6,449,362) | (15,715,315) |
OTHER INCOME (EXPENSE) | ||
Interest expense | (31,417) | (55,819) |
Other income | 35 | 0 |
Change in fair value of derivative liability warrants | (1,387,500) | 0 |
Loss on extinguishment of debt | 0 | (3,408,559) |
TOTAL OTHER EXPENSE, NET | (1,418,882) | (3,464,378) |
LOSS BEFORE INCOME TAXES | (7,868,244) | (19,179,693) |
PROVISION FOR INCOME TAXES (BENEFIT) | 0 | 0 |
NET LOSS | (7,868,244) | (19,179,693) |
Consulting Services [Member] | ||
Sales | ||
Total sales | 0 | 0 |
Other Sales [Member] | ||
Sales | ||
Total sales | $ 0 | $ 0 |
CONDENSED CONSOLIDATED STATEM_2
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (Parenthetical) - $ / shares | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
Income Statement [Abstract] | ||
Earnings Per Share, Basic | $ (0.39) | $ (1.52) |
Earnings Per Share, Diluted | $ (0.39) | $ (1.52) |
Weighted Average Number of Shares Outstanding, Basic | 20,084,169 | 12,606,099 |
Weighted Average Number of Shares Outstanding, Diluted | 20,084,169 | 12,606,099 |
CONDENSED CONSOLIDATED STATEM_3
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited) - USD ($) | Preferred Stock [Member] | Common Stock [Member] | Additional Paid-in Capital [Member] | Common Stock Subscribed [Member] | Treasury Stock, Common [Member] | Retained Earnings [Member] | Total |
Beginning balance, value at Dec. 31, 2021 | $ 1 | $ 1,196 | $ 30,146,728 | $ 0 | $ (247,165) | $ (27,550,126) | $ 2,350,634 |
Balance at beginning, shares at Dec. 31, 2021 | 8,000 | 12,492,050 | |||||
Shares issued for cash | $ 14 | 1,265,986 | 1,266,000 | ||||
Shares issued for cash, shares | 142,158 | ||||||
Shares issued and subscribed for services | $ 40 | 3,539,960 | 3,540,000 | ||||
Shares issued for services, shares | 397,505 | ||||||
Retirement of shares | (247,165) | 247,165 | |||||
Retirement of shares, shares | (110,762) | ||||||
Warrants converted to shares* | $ 2 | 107,498 | 2,500 | 110,000 | |||
Warrants converted to shares, shares | 24,704 | ||||||
Warrants issued for services | 10,841,695 | 10,841,695 | |||||
Warrants issued for extinguishment of debt | 3,408,559 | 3,408,559 | |||||
Net income (loss) | (19,179,693) | (19,179,693) | |||||
Ending balance, value at Mar. 31, 2022 | $ 1 | $ 1,252 | 49,063,261 | 2,500 | 0 | (46,729,819) | 2,337,195 |
Balance at ending, shares at Mar. 31, 2022 | 8,000 | 12,945,654 | |||||
Beginning balance, value at Dec. 31, 2022 | $ 1,957 | 70,541,095 | (65,739,723) | 4,803,329 | |||
Balance at beginning, shares at Dec. 31, 2022 | 19,566,839 | ||||||
Shares issued for cash | |||||||
Shares issued and subscribed for services | $ 137 | 2,396,677 | 720,000 | 3,116,814 | |||
Shares issued for services, shares | 1,374,197 | ||||||
Warrants issued for services | 1,111,706 | 1,111,706 | |||||
Net income (loss) | (7,868,244) | (7,868,244) | |||||
Stock based compensation | 122,391 | 122,391 | |||||
Ending balance, value at Mar. 31, 2023 | $ 0 | $ 2,094 | $ 74,171,869 | $ 720,000 | $ 0 | $ (73,607,967) | $ 1,285,996 |
Balance at ending, shares at Mar. 31, 2023 | 0 | 20,941,036 |
CONSOLIDATED CONDENSED STATEMEN
CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
OPERATING ACTIVITIES | ||
Net loss | $ (7,868,244) | $ (19,179,693) |
Adjustments to reconcile net loss to net cash provided by (used in) operating activities | ||
Depreciation and amortization | 250,309 | 250,346 |
Change in fair value of derivative liability warrants | 1,387,500 | 0 |
Stock based compensation | 122,391 | 0 |
Shares issued for services | 2,396,814 | 3,540,000 |
Shares subscribed for services | 720,000 | 0 |
Warrants issued for extinguishment of debt | 1,111,706 | 3,408,559 |
Warrants issued for services | 0 | 10,841,695 |
Increase (decrease) in: | ||
Accounts receivable | 8,075 | 0 |
Prepaid expenses | 20,709 | 0 |
Right of use asset/liability | (208) | 1,251 |
Accounts payable | 143,432 | 110,701 |
Accrued expenses | 23,046 | 65,413 |
NET CASH USED IN OPERATING ACTIVITIES | (1,684,470) | (961,729) |
INVESTING ACTIVITIES | ||
Purchase of license right | 0 | 0 |
Purchase of property and equipment | 0 | 0 |
NET CASH USED IN INVESTING ACTIVITIES | 0 | 0 |
FINANCING ACTIVITIES | ||
Repayment of notes payable | 0 | (250,000) |
Shares issued for cash | 0 | 1,266,000 |
Shares issued for cash for the conversion warrants | 0 | 107,500 |
Cash received for stock subscription | 0 | 2,500 |
NET CASH PROVIDED BY FINANCING ACTIVITIES | 0 | 1,126,000 |
NET INCREASE (DECREASE) IN CASH | (1,684,470) | 164,271 |
CASH AT BEGINNING OF PERIOD | 3,791,302 | 2,179,558 |
CASH AT END OF PERIOD | 2,106,832 | 2,343,829 |
SUPPLEMENTAL DISCLOSURES | ||
Interest paid | 0 | 0 |
Taxes paid (refunded) | $ 0 | $ 0 |
DESCRIPTION OF BUSINESS AND BAS
DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION | 3 Months Ended |
Mar. 31, 2023 | |
Accounting Policies [Abstract] | |
DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION | NOTE 1 – DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION Nature of Business General The Merger Transaction About the Company’s Subsidiaries Our current business model is designed around furthering the development of our current product portfolio. We are continually exploring partnership opportunities with companies that have novel therapies in various stages of development or companies with technologies that improve the way that drugs are delivered to patients. We seek the best strategic relationships, which relationships could include in-license agreements, out-license agreements, co-development arrangements and other strategic partnerships in new and exciting therapeutic areas such as auto-immune disease and oncology. Basis of Presentation – As a result of the Merger, the condensed consolidated financial statements included in this report reflect (1) the historical operating results of Coeptis prior to the Merger; (2) the combined results of the Company and Coeptis following the closing of the Merger; (3) the assets and liabilities of Coeptis at their historical cost; and (4) the Company’s equity structure for all periods presented. Principles of Consolidation Risks and Uncertainties |
SUMMARY OF SIGNIFICANT ACCOUNTI
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | 3 Months Ended |
Mar. 31, 2023 | |
Accounting Policies [Abstract] | |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The Company’s significant accounting policies are described in Note 2 “Summary of Significant Accounting Policies,” in the Company’s Annual Report on Form 10-K filed with the SEC on March 29, 2023. There have been no material changes to the significant accounting policies during the three month period ended March 31, 2023, except for items mentioned below. Use of Estimates – Employee and Non-Employee Share-Based Compensation The Company applies ASC 718-10, “Share-Based Payment,” which requires the measurement and recognition of compensation expenses for all share-based payment awards made to employees and directors including employee stock options equity awards issued to employees and non-employees based on estimated fair values. ASC 718-10 requires companies to estimate the fair value of equity-based option awards on the date of grant using an option-pricing model. The fair value of the award is recognized as an expense on a straight-line basis over the requisite service periods in the Company’s consolidated statements of operations. The Company recognizes share-based award forfeitures as they occur. The Company estimates the fair value of granted option equity awards using a Black-Scholes options pricing model. The option-pricing model requires a number of assumptions, of which the most significant are share price, expected volatility and the expected option term (the time from the grant date until the options are exercised or expire). Expected volatility is estimated based on volatility of the Company. The Company has historically not paid dividends and has no foreseeable plans to issue dividends. The risk-free interest rate is based on the yield from governmental zero-coupon bonds with an equivalent term. The expected option term is calculated for options granted to employees and directors using the “simplified” method. Changes in the determination of each of the inputs can affect the fair value of the options granted and the results of operations of the Company. Adoption of New Accounting Pronouncements During the quarter ended March 31, 2023 and 2022, there were several new accounting pronouncements issued by the FASB. Each of these pronouncements, as applicable, has been or will be adopted by the Company. Management does not believe the adoption of any of these accounting pronouncements has had or will have a material impact on the Company’s financial statements. Going Concern – 73,607,967 |
LICENSE RIGHT
LICENSE RIGHT | 3 Months Ended |
Mar. 31, 2023 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
LICENSE RIGHT | NOTE 3 – LICENSE RIGHT Prior to 2021, the Company entered into an agreement with a foreign entity to market, distribute, and sell the Consensi product (Product) on an exclusive basis within the United States and Puerto Rico. Upon execution of the Agreement the Company paid $1,000,000 to the foreign entity. Milestone payments were due as follows; (1) $1,500,000 upon completion of the CMC Plan as reimbursements of costs incurred by the foreign entity, (2) $1,000,000 was due upon first commercial sale of the Product which occurred in June 2020. Milestones were met and paid in 2020. In September of 2021, the Company executed a license termination agreement with the foreign entity to cease all efforts for sales and promotion of the product in the United States and Puerto Rico. The termination included (i) issuance of $1,500,000 of convertible debt due in 2023 to satisfy amounts owed for the license, (ii) the issue of warrants (See NOTE 5) and (iii) transfer of inventory ownership back to the foreign entity. In conjunction with this termination, the Company also terminated its marketing agreement with a third party for the Product’s sales and promotion. During the year ended December 31, 2021, the Company and VyGen-Bio, Inc. (“Vy-Gen”) entered into agreements to jointly develop and commercialize two Vy-Gen product candidates, CD38-GEAR-NK and CD38-Diagnostic (the “CD38 Assets”). The Company paid $ 1,750,000 3,250,000 5,000,000 250,000 1,500,000 0 The Company made certain judgements as the basis in determining the accounting treatment of these options. The CD38 Assets represent a platform technology and a diagnostic tool which have multiple applications and uses. Both projects are intended to be used in more than one therapy or diagnostic option. For example, GEAR-NK is a technology which allows for the gene editing of human natural killer cells, so that these cells can no longer bind and be destroyed by targeted monoclonal antibody treatments. The GEAR-NK technology can be modified to work concomitantly with many different monoclonal antibody treatments in which there are currently over 100 approved by the FDA. Anti-CD38 is only the first class of monoclonal antibody treatments being developed under the GEAR-NK platform. Therefore, the pursuit of FDA approval for the use of CD38 assets for at least one indication or medical device approval is at least reasonably expected. Further, as the diagnostic asset may be used as an in vitro technology, it could be classified as a medical device, and therefore toxicity studies would not be a contingency to be resolved before reasonably establishing future value assumptions. In addition, there is perceived value in the CD38 assets, based on publicly disclosed current business deals in cell therapies, the developing market for these innovative technologies, and current interest from third parties in these technologies. The Company may sell or license its right to another party, with the written consent of VyGen Bio, which cannot be unreasonably withheld. Furthermore, the Company believes that any negative results from ongoing development of a single therapy or use, would not result in abandoning the project. Given these considerations, The Company has determined that these options have alternative future use and should be recorded as assets pursuant to ASC 730-10-25-2, Research and Development Related to the joint development, the Company, under the direction of the joint steering committee, is assessing market opportunities, intellectual property protection, and potential regulatory strategies for the CD38 Assets. VyGen Bio is responsible for development activities conducted and overseen by the scientists at Karolinska Institute. The agreement does not currently require additional payments for R&D costs by the Company and no additional payments are required upon development or regulatory milestones. |
DEBT
DEBT | 3 Months Ended |
Mar. 31, 2023 | |
Debt Disclosure [Abstract] | |
DEBT | NOTE 4 – DEBT In January 2020, the Company entered into a Senior Secured Note agreement with an unrelated party. The principal amount of $ 500,000 8 July 31, 2022 400,000 1.50 500,000 135,671 In January 2020, the Company entered into a Senior Secured Note agreement with an unrelated party. The principal amount of $ 167,000 8 July 31, 2022 250,000 1.50 50,000 117,000 42,893 In September 2021, as part of a termination of a license agreement with Purple BioTech (“Purple”), the Company issued a convertible note in the principal amount of $ 1,500,000 5 Loans under the CARES Act 77,500 77,595 0 0 On July 8, 2020, the Company received a loan of $ 150,000 3.75 150,000 Maturities of long-term debt are as follows for the years ended December 31, Schedule of maturities for long-term debt 2023 $ – 2024 – 2025 – 2026 – 2027 1,687 Thereafter 148,313 Total long-term debt $ 150,000 Derivative Liability Warrants - At March 31, 2023, there were (i) 7,500,000 3,750,000 The Company may call the Public Warrants for redemption, in whole and not in part, at a price of $0.01 per warrant: · at any time while the Public Warrants are exercisable, · upon not less than 30 days’ prior written notice of redemption to each Public Warrant holder, · if, and only if, the reported last sale price of the ordinary shares equals or exceeds $16.50 per share, for any 20 trading days within a 30-trading day period ending on the third trading day prior to the notice of redemption to Public Warrant holders, and · if, and only if, there is a current registration statement in effect with respect to the ordinary shares underlying such warrants at the time of redemption and for the entire 30-day trading period referred to above and continuing each day thereafter until the date of redemption. If the Company calls the Public Warrants for redemption, management will have the option to require all holders that wish to exercise the Public Warrants to do so on a “cashless basis,” as described in the warrant agreement. The exercise price and number of ordinary shares issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a share dividend, extraordinary dividend or recapitalization, reorganization, merger or consolidation. However, except as described above, the warrants will not be adjusted for issuances of ordinary shares at a price below its exercise price. Additionally, in no event will the Company be required to net cash settle the warrants. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company’s assets held outside of the Trust Account with respect to such warrants. Accordingly, the warrants may expire worthless. The Private Placement Warrants are identical to the Public Warrants, except that the Private Placement Warrants only allow the holder thereof to one ordinary share. Additionally, the Private Placement Warrants will be exercisable on a cashless basis and be non-redeemable so long as they are held by the initial purchasers or their permitted transferees. If the Private Placement Warrants are held by someone other than the initial purchasers or their permitted transferees, the Private Placement Warrants will be redeemable by the Company and exercisable by such holders on the same basis as the Public Warrants. ASC Section 815-40-15 addresses equity versus liability treatment and classification of equity-linked financial instruments, including warrants, and states that a warrant may be classified as a component of equity only if, among other things, the warrant is indexed to the issuer’s ordinary share. Under ASC Section 815-40-15, a warrant is not indexed to the issuer’s ordinary share if the terms of the warrant require an adjustment to the exercise price upon a specified event and that event is not an input to the fair value of the warrant. Based on management’s evaluation, the Company’s audit committee, in consultation with management, concluded that the Company’s Private Placement Warrants and Public Warrants are not indexed to the Company’s ordinary share in the manner contemplated by ASC Section 815-40-15 because the holder of the instrument is not an input into the pricing of a fixed-for-fixed option on equity shares. In addition, based on management’s evaluation, the Company’s audit committee, in consultation with management, concluded that certain warrant provisions preclude equity treatment as by ASC Section 815-10-15. The Company accounts for its Public Warrants and Private Placement Warrants as liabilities as set forth in ASC 815-40-15-7D and 7F. See below for details over the methodology and valuation of the Warrants. The Company follows the guidance in ASC Topic 820, Fair Value Measurement The fair value of the Company’s financial assets and liabilities reflects management’s estimate of amounts that the Company would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities: Level 1: Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis. Level 2: Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active. Level 3: Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability. The following table presents information about the Company’s assets that are measured at fair value on a recurring basis at March 31, 2023 and December 31, 2022, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: Schedule of fair value of warrants Description Level March 31, December 31, Warrant Liability – Public Warrants 1 $ 1,125,000 $ 750,000 Warrant Liability – Private Placement Warrants 3 $ 1,387,500 $ 375,000 The Warrants are accounted for as liabilities in accordance with ASC 815-40 and are presented within warrant liabilities on the accompanying consolidated balance sheets. The warrant liabilities are measured at fair value at inception and on a recurring basis, with changes in fair value presented in the consolidated statements of operations. The Warrants were valued using a binomial lattice model, which is considered to be a Level 3 fair value measurement. The binomial lattice model’s primary unobservable input utilized in determining the fair value of the Warrants is the expected volatility of the ordinary shares. The expected volatility as of the Initial Public Offering date was derived from observable public warrant pricing on comparable ‘blank-check’ companies without an identified target. For periods subsequent to the detachment of the Public Warrants from the Units, the close price of the Public Warrant price will be used as the fair value as of each relevant date. The following table provides quantitative information regarding Level 3 fair value measurements: Schedule of fair value assumptions March 31, December 31, Risk-free interest rate 3.61% 3.97% Expected volatility 83.2% 67.1% Exercise price $ 11.50 $ 11.50 Stock Price $ 1.44 $ 1.53 The following table presents the changes in the fair value of warrant liabilities: Schedule of changes in fair value of warrant liabilities Private Placement Public Warrant Liabilities Fair value as of December 31, 2022 $ 375,000 $ 750,000 $ 1,125,000 Change in valuation inputs 1,012,500 375,000 1,387,500 Fair value as of March 31, 2023 $ 1,387,500 $ 1,125,000 $ 2,512,500 There were no |
CAPITAL STRUCTURE
CAPITAL STRUCTURE | 3 Months Ended |
Mar. 31, 2023 | |
Equity [Abstract] | |
CAPITAL STRUCTURE | NOTE 5 – CAPITAL STRUCTURE The total number of shares of stock which the corporation shall have authority to issue is 160,000,000 shares, of which 150,000,000 0.0001 10,000,000 0.0001 Common Stock 20,941,036 19,566,839 In 2022, Coeptis Therapeutics Holdings, Inc., raised capital by issuance of common stock above the stated par value. The contributed capital recognized as additional paid in capital during the quarters ended March 31, 2023 and 2022 was $ 0 0 Treasury Stock 110,762 247,165 110,762 no Preferred Stock no 8,000 Stock Based Compensation – A summary of the Company’s stock option activity is as follows: Schedule of option activity Shares Underlying Options Weighted Average Exercise Price Weighted Average Contractual Life (Years) Intrinsic Value Outstanding at December 31, 2022 – – Granted 1,457,500 $ 2.18 8.53 $ – Forfeited – – Exercised – – Outstanding at March 31, 2023 1,457,500 $ 2.18 8.53 $ – For the three months ended March 31, 2023 and 2022, the Company recorded $ 122,391 0 1,320,050 The options granted during the three months ended March 31, 2023 were valued using the Black-Scholes option pricing model using the following weighted average assumptions: Options assumptions For the three months ended March 31, 2023 Expected term, in years 5.38 Expected volatility 79.35% Risk-free interest rate 3.66% Dividend yield – Common Stock Warrants As a result of the Merger on October 28, 2022, all surviving warrants from Coeptis Therapeutics, Inc. were converted using a 2.9685:1 ratio, and became exercisable to acquire shares of the Company’s common stock. On November 23, 2020, Coeptis Therapeutics, Inc. (under its prior name Vinings Holdings Inc.) issued a class A and a class B warrant to Coral Investment Partners, LP (“CIP”), with each warrant granting CIP the right to purchase 500,000 2 5 November 30, 2023 336,869 Warrant Holder 1 500,000 1 500,000 2 500,000 5 June 1, 2026 2,500 504,461 Warrant Holder 2 200,000 1 100,000 2 100,000 5 July 26, 2026 5,000 195,000 75,000 25,000 33,687 On September 22, 2021, Coeptis Therapeutics, Inc. issued a warrant in conjunction with the termination of the license right (see Note 3) with Purple, granting Purple the right to purchase 300,000 5 1,897,585 101,061 Warrant Holder 3 600,000 1 December 20, 2026 300,000 175,000 115,000 10,000 no Warrant Holder 4 300,000 300,000 no Warrant Holder 5 175,000 200,000 126,326 Warrant Holder 6 250,000 1.50 January 31, 2024 84,217 Warrant Holder 7 400,000 1.50 January 31, 2024 134,747 Warrant Holder 8 775,000 1.50 January 31, 2024 775,000 no Warrant Holder 9 200,000 1.50 January 31, 2024 200,000 no Warrant Holder 10 350,000 1.50 January 31, 2024 53,334 50,000 246,666 no Warrant Holder 11 150,000 1 150,000 2 January 31, 2024 170,000 1.50 January 31, 2024 158,328 Warrant Holder 12 1,018,050 1.50 January 31, 2024 100,000 918,050 no Warrant Holder 13 225,000 1.50 January 31, 2024 15,000 210,000 no Warrant Holder 14 - 100,000 1 January 31, 2024 100,000 no Warrant Holder 15 - 100,000 1.50 January 31, 2024 100,000 no Warrant Holder 16 - 100,000 1.50 January 31, 2024 25,000 75,000 no Warrant Holder 17 - 52,050 1.50 January 31, 2024 52,050 no Warrant Holder 18 - 250,000 3 March 30, 2024 84,217 Warrant Holder 19 - 300,000 1.50 April 1, 2027 300,000 no Warrant Holder 20 - 100,000 2.50 January 2, 2027 Warrant Holder 21 - 250,000 1.90 January 19, 2027 The warrants issued since May 28, 2021 and as of March 31, 2023 were valued using the Black-Scholes option pricing model using the following assumptions: 1) exercise price ranging from $1.00 to $5.00 per share, 2) fair value ranging from $4.80 to $6.00 per share, 3) discount rate ranging from 1.15% to 2.31%, 3) dividend rate of 0%, and 4) a term ranging from 2 to 5 years. On April 19, 2022, Coeptis Therapeutics, Inc. initiated a warrant conversion call for certain warrants and on April 20, 2022, for additional warrants. The original expiration for the warrant conversions was set as May 19, 2022, and May 20, 2022. The expiration date was extended and moved to June 30, 2022. A second extension moved the expiration to July 15, 2022, and the third extension moved the expiration date for the warrant conversions to August 1, 2022. The final extension was extended and moved to September 13, 2022. Warrants that were part of the call and not exercised by this date expired. Schedule of warrants outstanding $ 1.00 $ 1.50 $ 1.90 $ 2.00 $ 2.50 $ 3.00 $ 5.00 Warrant contract # Shares $ 2.97 $ 4.45 $ 5.94 $ 8.91 $ 14.84 Coral Investment Partners Warrants 1,000,000 – – – 500,000 – – 500,000 Coral Investment Partners Warrants, as converted 336,869 – – – 168,434 – – 168,434 Warrant Holder 1 1,500,000 500,000 – – 500,000 – – 500,000 July 28, 2022 (2,500 ) (2,500 ) – – – – – – 1,497,500 497,500 – – 500,000 – – 500,000 Warrant Holder 1, as converted 504,461 167,592 – – 168,434 – – 168,434 Warrant Holder 2 400,000 200,000 – – 100,000 – – 100,000 March 1, 2022 (5,000 ) (5,000 ) – – – – – – June 27, 2022 (270,000 ) (195,000 ) – – (75,000 ) – – – Expired - September 13, 2022 (25,000 ) – – – (25,000 ) – – – 100,000 – – – – – – 100,000 Warrant Holder 2, as converted 33,687 – – – – – – 33,687 Purple BioTech 300,000 – – – – – – 300,000 Purple BioTech, as converted 101,061 – – – – – – 101,061 Warrant Holder 3 600,000 600,000 – – – – – – Transfer to Warrant Holder 4 (300,000 ) (300,000 ) – – – – – – Transfer to Warrant Holder 5 (175,000 ) (175,000 ) – – – – – – August 19, 2022 (115,000 ) (115,000 ) – – – – – – Expired - September 13, 2022 (10,000 ) (10,000 ) – – – – – – – – – – – – – – Warrant Holder 3, as converted – – – – – – – – Warrant Holder 4 Transfer from Warrant Holder 3 300,000 300,000 – – – – – – August 19, 2022 (300,000 ) (300,000 ) – – – – – – – – – – – – – – Warrant Holder 4, as converted – – – – – – – – Warrant Holder 5 Transfer from Warrant Holder 3 175,000 175,000 – – – – – – Transfer from Warrant Holder 9 200,000 – 200,000 – – – – – 375,000 175,000 200,000 – – – – – Warrant Holder 5, as converted 126,326 58,952 67,374 – – – – – $ 1.00 $ 1.50 $ 1.90 $ 2.00 $ 2.50 $ 3.00 $ 5.00 Warrant contract # Shares $ 2.97 $ 4.45 $ 5.94 $ 8.91 $ 14.84 Warrant Holder 6 250,000 – 250,000 – – – – – Warrant Holder 6, as converted 84,217 – 84,217 – – – – – Warrant Holder 7 400,000 – 400,000 – – – – – Warrant Holder 7, as converted 134,747 – 134,747 – – – – – Warrant Holder 8 775,000 – 775,000 – – – – – September 14, 2022 (775,000 ) – (775,000 ) – – – – – – – – – – – – – Warrant Holder 8, as converted – – – – – – – – Warrant Holder 9 200,000 – 200,000 – – – – – Transfer to Warrant Holder 5 (200,000 ) – (200,000 ) – – – – – – – – – – – – – Warrant Holder 9, as converted – – – – – – – – Warrant Holder 10 350,000 – 350,000 – – – – – March 1, 2022 (53,334 ) – (53,334 ) – – – – – August 19, 2022 (50,000 ) – (50,000 ) – – – – – September 14, 2022 (246,666 ) – (246,666 ) – – – – – – – – – – – – – Warrant Holder 10, as converted – – – – – – – – Warrant Holder 11 300,000 150,000 – – 150,000 – – – April 14, 2022 170,000 – 170,000 – – – – – 470,000 150,000 170,000 – 150,000 – – – Warrant Holder 11, as converted 158,328 50,530 57,268 – 50,530 – – – Warrant Holder 12 1,018,050 – 1,018,050 – – – – – August 19, 2022 (100,000 ) – (100,000 ) – – – – – September 14, 2022 (918,050 ) – (918,050 ) – – – – – – – – – – – – – Warrant Holder 12, as converted – – – – – – – – Warrant Holder 13 225,000 – 225,000 – – – – – March 1, 2022 (15,000 ) – (15,000 ) – – – – – September 14, 2022 (210,000 ) – (210,000 ) – – – – – – – – – – – – – Warrant Holder 13, as converted – – – – – – – – $ 1.00 $ 1.50 $ 1.90 $ 2.00 $ 2.50 $ 3.00 $ 5.00 Warrant contract # Shares $ 2.97 $ 4.45 $ 5.94 $ 8.91 $ 14.84 Warrant Holder 14 100,000 100,000 – – – – – – August 19, 2022 (100,000 ) (100,000 ) – – – – – – – – – – – – – – Warrant Holder 14, as converted – – – – – – – – Warrant Holder 15 100,000 – 100,000 – – – – – September 14, 2022 (100,000 ) – (100,000 ) – – – – – – – – – – – – – Warrant Holder 15, as converted – – – – – – – – Warrant Holder 16 100,000 – 100,000 – – – – – June 27, 2022 (25,000 ) – (25,000 ) – – – – – September 14, 2022 (75,000 ) – (75,000 ) – – – – – – – – – – – – – Warrant Holder 16, as converted – – – – – – – – Warrant Holder 17 52,050 – 52,050 – – – – – September 14, 2022 (52,050 ) – (52,050 ) – – – – – – – – – – – – – Warrant Holder 17, as converted – – – – – – – – Warrant Holder 18 250,000 – – – – – 250,000 – Warrant Holder 18, as converted 84,217 – – – – – 84,217 – Warrant Holder 19 300,000 – 300,000 – – – – – (300,000 ) – (300,000 ) – – – – – – – – – – – – – Warrant Holder 19, as converted – – – – – – – – Warrant Holder 20 – – – – – – – – January 3, 2023 100,000 – – – – 100,000 – – Warrant Holder 20 100,000 – – – – 100,000 – – Warrant Holder 21 – – – – – – – – January 20, 2023 250,000 – – 250,000 – – – – Warrant Holder 21 250,000 – – 250,000 – – – – Total warrants outstanding for purchase of shares: 4,992,500 822,500 1,020,000 250,000 1,150,000 100,000 250,000 1,400,000 Total warrants outstanding for purchase of shares, as converted: 1,913,912 277,074 343,606 250,000 387,399 100,000 84,217 471,616 Options/Stock Awards – the Company granted options to purchase an aggregate of 1,357,500 shares of our common stock under the 2022 Equity Incentive Plan, to various officers, directors, employees and consultants, at an average exercise price of . The Company has also granted a stand-alone option to a former employee to purchase up to 100,000 shares of our common stock at an exercise price of $10 per share. |
COMMITMENTS AND CONTINGENCIES
COMMITMENTS AND CONTINGENCIES | 3 Months Ended |
Mar. 31, 2023 | |
Commitments and Contingencies Disclosure [Abstract] | |
COMMITMENTS AND CONTINGENCIES | NOTE 6 – COMMITMENTS AND CONTINGENCIES Leases Leases 11,250 Future minimum rental payments required under the lease are as follows: Schedule of future minimum rental payments 2023 $ 33,750 2024 18,750 Total minimum lease payments: 52,500 Less amount representing interest (6,216 ) Present value of minimum lease payments: $ 46,284 As of March 31, 2023, the Company had recorded a right of use asset of $ 49,065 31,561 14,723 Legal Matters Royalty Obligations - 0 0 Royalty Advances 1,000,000 1,000,000 no Potential Asset Acquisition University of Pittsburgh Option Agreement CAR T License 75,000 annual maintenance fees ranging between $15,000 and $25,000 716,714 Registration Rights Pursuant to a registration rights agreement entered into on October 29, 2020, the holders of the founder shares, the Private Placement Warrants and underlying securities, and any securities issued upon conversion of Working Capital Loans (and underlying securities) would be entitled to registration rights pursuant to a registration rights agreement. The holders of at least a majority in interest of the then-outstanding number of these securities were entitled to make up to three demands, excluding short form demands, that the Company register such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the consummation of a Business Combination. Notwithstanding the foregoing, Imperial, I-Bankers and Northland did not exercise their demand and “piggyback” registration rights after five (5) and seven (7) years after the effective date of the registration statement and did not exercise its demand rights on more than one occasion. The registration rights agreement did not contain liquidating damages or other cash settlement provisions resulting from delays in registering the Company’s securities. The Company would bear the expenses incurred in connection with the filing of any such registration statements. |
401(k) PROFIT-SHARING PLAN
401(k) PROFIT-SHARING PLAN | 3 Months Ended |
Mar. 31, 2023 | |
Retirement Benefits [Abstract] | |
401(k) PROFIT-SHARING PLAN | NOTE 7 - 401(k) PROFIT-SHARING PLAN The Company sponsors a qualified profit-sharing plan with a 401(k) feature that covers all eligible employees. Participation in the 401(k) feature of the plan is voluntary. Participating employees may defer up to 100% of their compensation up to the maximum prescribed by the Internal Revenue Code. The plan permits for employee elective deferrals but has no contribution requirements for the Company. During the quarters ended March 31, 2023 and 2022, no |
INCOME TAXES
INCOME TAXES | 3 Months Ended |
Mar. 31, 2023 | |
Income Tax Disclosure [Abstract] | |
INCOME TAXES | NOTE 8 – INCOME TAXES no income tax expense or benefit was recognized. The Company’s deferred tax assets are comprised primarily of net operating loss carryforwards. The Company maintains a full valuation allowance on its deferred tax assets since it has not yet achieved sustained profitable operations. As a result, the Company has not recorded any income tax benefit since its inception. |
SUBSEQUENT EVENTS
SUBSEQUENT EVENTS | 3 Months Ended |
Mar. 31, 2023 | |
Subsequent Events [Abstract] | |
SUBSEQUENT EVENTS | NOTE 9 – SUBSEQUENT EVENTS Management has performed a review of items occurring after March 31, 2023 to determine if there were any that would require adjustment to in disclosure in the accompanying consolidated financial statements noting no such items. |
SUMMARY OF SIGNIFICANT ACCOUN_2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) | 3 Months Ended |
Mar. 31, 2023 | |
Accounting Policies [Abstract] | |
Use of Estimates – | Use of Estimates – |
Employee and Non-Employee Share-Based Compensation – | Employee and Non-Employee Share-Based Compensation The Company applies ASC 718-10, “Share-Based Payment,” which requires the measurement and recognition of compensation expenses for all share-based payment awards made to employees and directors including employee stock options equity awards issued to employees and non-employees based on estimated fair values. ASC 718-10 requires companies to estimate the fair value of equity-based option awards on the date of grant using an option-pricing model. The fair value of the award is recognized as an expense on a straight-line basis over the requisite service periods in the Company’s consolidated statements of operations. The Company recognizes share-based award forfeitures as they occur. The Company estimates the fair value of granted option equity awards using a Black-Scholes options pricing model. The option-pricing model requires a number of assumptions, of which the most significant are share price, expected volatility and the expected option term (the time from the grant date until the options are exercised or expire). Expected volatility is estimated based on volatility of the Company. The Company has historically not paid dividends and has no foreseeable plans to issue dividends. The risk-free interest rate is based on the yield from governmental zero-coupon bonds with an equivalent term. The expected option term is calculated for options granted to employees and directors using the “simplified” method. Changes in the determination of each of the inputs can affect the fair value of the options granted and the results of operations of the Company. |
Adoption of New Accounting Pronouncements | Adoption of New Accounting Pronouncements During the quarter ended March 31, 2023 and 2022, there were several new accounting pronouncements issued by the FASB. Each of these pronouncements, as applicable, has been or will be adopted by the Company. Management does not believe the adoption of any of these accounting pronouncements has had or will have a material impact on the Company’s financial statements. |
Going Concern | Going Concern – 73,607,967 |
DEBT (Tables)
DEBT (Tables) | 3 Months Ended |
Mar. 31, 2023 | |
Debt Disclosure [Abstract] | |
Schedule of maturities for long-term debt | Schedule of maturities for long-term debt 2023 $ – 2024 – 2025 – 2026 – 2027 1,687 Thereafter 148,313 Total long-term debt $ 150,000 |
Schedule of fair value of warrants | Schedule of fair value of warrants Description Level March 31, December 31, Warrant Liability – Public Warrants 1 $ 1,125,000 $ 750,000 Warrant Liability – Private Placement Warrants 3 $ 1,387,500 $ 375,000 |
Schedule of fair value assumptions | Schedule of fair value assumptions March 31, December 31, Risk-free interest rate 3.61% 3.97% Expected volatility 83.2% 67.1% Exercise price $ 11.50 $ 11.50 Stock Price $ 1.44 $ 1.53 |
Schedule of changes in fair value of warrant liabilities | Schedule of changes in fair value of warrant liabilities Private Placement Public Warrant Liabilities Fair value as of December 31, 2022 $ 375,000 $ 750,000 $ 1,125,000 Change in valuation inputs 1,012,500 375,000 1,387,500 Fair value as of March 31, 2023 $ 1,387,500 $ 1,125,000 $ 2,512,500 |
CAPITAL STRUCTURE (Tables)
CAPITAL STRUCTURE (Tables) | 3 Months Ended |
Mar. 31, 2023 | |
Equity [Abstract] | |
Schedule of option activity | Schedule of option activity Shares Underlying Options Weighted Average Exercise Price Weighted Average Contractual Life (Years) Intrinsic Value Outstanding at December 31, 2022 – – Granted 1,457,500 $ 2.18 8.53 $ – Forfeited – – Exercised – – Outstanding at March 31, 2023 1,457,500 $ 2.18 8.53 $ – |
Options assumptions | Options assumptions For the three months ended March 31, 2023 Expected term, in years 5.38 Expected volatility 79.35% Risk-free interest rate 3.66% Dividend yield – |
Schedule of warrants outstanding | Schedule of warrants outstanding $ 1.00 $ 1.50 $ 1.90 $ 2.00 $ 2.50 $ 3.00 $ 5.00 Warrant contract # Shares $ 2.97 $ 4.45 $ 5.94 $ 8.91 $ 14.84 Coral Investment Partners Warrants 1,000,000 – – – 500,000 – – 500,000 Coral Investment Partners Warrants, as converted 336,869 – – – 168,434 – – 168,434 Warrant Holder 1 1,500,000 500,000 – – 500,000 – – 500,000 July 28, 2022 (2,500 ) (2,500 ) – – – – – – 1,497,500 497,500 – – 500,000 – – 500,000 Warrant Holder 1, as converted 504,461 167,592 – – 168,434 – – 168,434 Warrant Holder 2 400,000 200,000 – – 100,000 – – 100,000 March 1, 2022 (5,000 ) (5,000 ) – – – – – – June 27, 2022 (270,000 ) (195,000 ) – – (75,000 ) – – – Expired - September 13, 2022 (25,000 ) – – – (25,000 ) – – – 100,000 – – – – – – 100,000 Warrant Holder 2, as converted 33,687 – – – – – – 33,687 Purple BioTech 300,000 – – – – – – 300,000 Purple BioTech, as converted 101,061 – – – – – – 101,061 Warrant Holder 3 600,000 600,000 – – – – – – Transfer to Warrant Holder 4 (300,000 ) (300,000 ) – – – – – – Transfer to Warrant Holder 5 (175,000 ) (175,000 ) – – – – – – August 19, 2022 (115,000 ) (115,000 ) – – – – – – Expired - September 13, 2022 (10,000 ) (10,000 ) – – – – – – – – – – – – – – Warrant Holder 3, as converted – – – – – – – – Warrant Holder 4 Transfer from Warrant Holder 3 300,000 300,000 – – – – – – August 19, 2022 (300,000 ) (300,000 ) – – – – – – – – – – – – – – Warrant Holder 4, as converted – – – – – – – – Warrant Holder 5 Transfer from Warrant Holder 3 175,000 175,000 – – – – – – Transfer from Warrant Holder 9 200,000 – 200,000 – – – – – 375,000 175,000 200,000 – – – – – Warrant Holder 5, as converted 126,326 58,952 67,374 – – – – – $ 1.00 $ 1.50 $ 1.90 $ 2.00 $ 2.50 $ 3.00 $ 5.00 Warrant contract # Shares $ 2.97 $ 4.45 $ 5.94 $ 8.91 $ 14.84 Warrant Holder 6 250,000 – 250,000 – – – – – Warrant Holder 6, as converted 84,217 – 84,217 – – – – – Warrant Holder 7 400,000 – 400,000 – – – – – Warrant Holder 7, as converted 134,747 – 134,747 – – – – – Warrant Holder 8 775,000 – 775,000 – – – – – September 14, 2022 (775,000 ) – (775,000 ) – – – – – – – – – – – – – Warrant Holder 8, as converted – – – – – – – – Warrant Holder 9 200,000 – 200,000 – – – – – Transfer to Warrant Holder 5 (200,000 ) – (200,000 ) – – – – – – – – – – – – – Warrant Holder 9, as converted – – – – – – – – Warrant Holder 10 350,000 – 350,000 – – – – – March 1, 2022 (53,334 ) – (53,334 ) – – – – – August 19, 2022 (50,000 ) – (50,000 ) – – – – – September 14, 2022 (246,666 ) – (246,666 ) – – – – – – – – – – – – – Warrant Holder 10, as converted – – – – – – – – Warrant Holder 11 300,000 150,000 – – 150,000 – – – April 14, 2022 170,000 – 170,000 – – – – – 470,000 150,000 170,000 – 150,000 – – – Warrant Holder 11, as converted 158,328 50,530 57,268 – 50,530 – – – Warrant Holder 12 1,018,050 – 1,018,050 – – – – – August 19, 2022 (100,000 ) – (100,000 ) – – – – – September 14, 2022 (918,050 ) – (918,050 ) – – – – – – – – – – – – – Warrant Holder 12, as converted – – – – – – – – Warrant Holder 13 225,000 – 225,000 – – – – – March 1, 2022 (15,000 ) – (15,000 ) – – – – – September 14, 2022 (210,000 ) – (210,000 ) – – – – – – – – – – – – – Warrant Holder 13, as converted – – – – – – – – $ 1.00 $ 1.50 $ 1.90 $ 2.00 $ 2.50 $ 3.00 $ 5.00 Warrant contract # Shares $ 2.97 $ 4.45 $ 5.94 $ 8.91 $ 14.84 Warrant Holder 14 100,000 100,000 – – – – – – August 19, 2022 (100,000 ) (100,000 ) – – – – – – – – – – – – – – Warrant Holder 14, as converted – – – – – – – – Warrant Holder 15 100,000 – 100,000 – – – – – September 14, 2022 (100,000 ) – (100,000 ) – – – – – – – – – – – – – Warrant Holder 15, as converted – – – – – – – – Warrant Holder 16 100,000 – 100,000 – – – – – June 27, 2022 (25,000 ) – (25,000 ) – – – – – September 14, 2022 (75,000 ) – (75,000 ) – – – – – – – – – – – – – Warrant Holder 16, as converted – – – – – – – – Warrant Holder 17 52,050 – 52,050 – – – – – September 14, 2022 (52,050 ) – (52,050 ) – – – – – – – – – – – – – Warrant Holder 17, as converted – – – – – – – – Warrant Holder 18 250,000 – – – – – 250,000 – Warrant Holder 18, as converted 84,217 – – – – – 84,217 – Warrant Holder 19 300,000 – 300,000 – – – – – (300,000 ) – (300,000 ) – – – – – – – – – – – – – Warrant Holder 19, as converted – – – – – – – – Warrant Holder 20 – – – – – – – – January 3, 2023 100,000 – – – – 100,000 – – Warrant Holder 20 100,000 – – – – 100,000 – – Warrant Holder 21 – – – – – – – – January 20, 2023 250,000 – – 250,000 – – – – Warrant Holder 21 250,000 – – 250,000 – – – – Total warrants outstanding for purchase of shares: 4,992,500 822,500 1,020,000 250,000 1,150,000 100,000 250,000 1,400,000 Total warrants outstanding for purchase of shares, as converted: 1,913,912 277,074 343,606 250,000 387,399 100,000 84,217 471,616 |
COMMITMENTS AND CONTINGENCIES (
COMMITMENTS AND CONTINGENCIES (Tables) | 3 Months Ended |
Mar. 31, 2023 | |
Commitments and Contingencies Disclosure [Abstract] | |
Schedule of future minimum rental payments | Schedule of future minimum rental payments 2023 $ 33,750 2024 18,750 Total minimum lease payments: 52,500 Less amount representing interest (6,216 ) Present value of minimum lease payments: $ 46,284 |
SUMMARY OF SIGNIFICANT ACCOUN_3
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($) | Mar. 31, 2023 | Dec. 31, 2022 |
Accounting Policies [Abstract] | ||
Retained Earnings (Accumulated Deficit) | $ 73,607,967 | $ 65,739,723 |
LICENSE RIGHT (Details Narrativ
LICENSE RIGHT (Details Narrative) - USD ($) | 1 Months Ended | 3 Months Ended | 12 Months Ended | ||
Nov. 30, 2022 | Mar. 31, 2022 | Mar. 31, 2023 | Mar. 31, 2022 | Dec. 31, 2021 | |
Finite-Lived Intangible Assets [Line Items] | |||||
Repayments of Notes Payable | $ 1,500,000 | $ 250,000 | $ 0 | $ 250,000 | |
CD38 Assets [Member] | |||||
Finite-Lived Intangible Assets [Line Items] | |||||
Notes Issued | $ 3,250,000 | ||||
Notes Payable, Noncurrent | 0 | ||||
CD38 Assets [Member] | |||||
Finite-Lived Intangible Assets [Line Items] | |||||
Payments to Acquire Intangible Assets | $ 1,750,000 | ||||
Capitalized Contract Cost, Gross | $ 5,000,000 |
DEBT (Details - Debt maturities
DEBT (Details - Debt maturities) | Mar. 31, 2023 USD ($) |
Debt Disclosure [Abstract] | |
2023 | $ 0 |
2024 | 0 |
2025 | 0 |
2026 | 0 |
2027 | 1,687 |
Thereafter | 148,313 |
Total long-term debt | $ 150,000 |
DEBT (Details - Fair value)
DEBT (Details - Fair value) - Fair Value, Recurring [Member] - USD ($) | Mar. 31, 2023 | Dec. 31, 2022 |
Public Warrants [Member] | Fair Value, Inputs, Level 1 [Member] | ||
Offsetting Assets [Line Items] | ||
Financial Liabilities Fair Value Disclosure | $ 1,125,000 | $ 750,000 |
Private Placement Warrants [Member] | Fair Value, Inputs, Level 3 [Member] | ||
Offsetting Assets [Line Items] | ||
Financial Liabilities Fair Value Disclosure | $ 1,387,500 | $ 375,000 |
DEBT (Details - Assumptions)
DEBT (Details - Assumptions) | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
Measurement Input, Risk Free Interest Rate [Member] | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Derivatives, Determination of Fair Value | 3.61% | 3.97% |
Measurement Input, Price Volatility [Member] | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Derivatives, Determination of Fair Value | 83.2% | 67.1% |
Measurement Input, Exercise Price [Member] | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Derivatives, Determination of Fair Value | 11.50 | 11.50 |
Measurement Input, Share Price [Member] | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Derivatives, Determination of Fair Value | 1.44 | 1.53 |
DEBT (Details - Changes in fair
DEBT (Details - Changes in fair value of warrant liabilities) | 3 Months Ended |
Mar. 31, 2023 USD ($) | |
Private Placement Warrants [Member] | |
Offsetting Assets [Line Items] | |
Fair value warrant liabilities at beginning | $ 375,000 |
Change in valuation inputs | 1,012,500 |
Fair value warrant liabilities at beginning | 1,387,500 |
Public Warrants [Member] | |
Offsetting Assets [Line Items] | |
Fair value warrant liabilities at beginning | 750,000 |
Change in valuation inputs | 375,000 |
Fair value warrant liabilities at beginning | 1,125,000 |
Warrant Liabilities [Member] | |
Offsetting Assets [Line Items] | |
Fair value warrant liabilities at beginning | 1,125,000 |
Change in valuation inputs | 1,387,500 |
Fair value warrant liabilities at beginning | $ 2,512,500 |
DEBT (Details Narrative)
DEBT (Details Narrative) - USD ($) | 1 Months Ended | 2 Months Ended | 3 Months Ended | |||||||
Apr. 14, 2022 | Jul. 08, 2020 | May 06, 2020 | Dec. 31, 2022 | Nov. 30, 2022 | Mar. 31, 2022 | Feb. 28, 2021 | Mar. 31, 2023 | Mar. 31, 2022 | Jan. 31, 2020 | |
Debt Instrument [Line Items] | ||||||||||
Repayments of Notes Payable | $ 1,500,000 | $ 250,000 | $ 0 | $ 250,000 | ||||||
Fair value transfer | 0 | |||||||||
License Agreement [Member] | Purple Bio Tech [Member] | ||||||||||
Debt Instrument [Line Items] | ||||||||||
Principal amount | $ 1,500,000 | |||||||||
Debt Instrument, Interest Rate During Period | 5% | |||||||||
Public Warrants [Member] | ||||||||||
Debt Instrument [Line Items] | ||||||||||
Warrants outstanding | 7,500,000 | |||||||||
Private Warrants [Member] | ||||||||||
Debt Instrument [Line Items] | ||||||||||
Warrants outstanding | 3,750,000 | |||||||||
Note Payable 1 [Member] | ||||||||||
Debt Instrument [Line Items] | ||||||||||
Principal amount | $ 500,000 | |||||||||
Debt maturity date | Jul. 31, 2022 | |||||||||
Repayments of Notes Payable | $ 500,000 | |||||||||
Interest Expense, Debt | 135,671 | |||||||||
Note Payable 1 [Member] | Debt Extension [Member] | Warrant [Member] | ||||||||||
Debt Instrument [Line Items] | ||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 400,000 | |||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 1.50 | |||||||||
Note Payable 2 [Member] | ||||||||||
Debt Instrument [Line Items] | ||||||||||
Principal amount | $ 167,000 | |||||||||
Debt stated interest rate | 8% | |||||||||
Debt maturity date | Jul. 31, 2022 | |||||||||
Repayments of Notes Payable | 50,000 | 117,000 | ||||||||
Interest Expense, Debt | $ 42,893 | |||||||||
Note Payable 2 [Member] | Debt Extension [Member] | Warrant [Member] | ||||||||||
Debt Instrument [Line Items] | ||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 250,000 | |||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 1.50 | |||||||||
PPP Loan [Member] | ||||||||||
Debt Instrument [Line Items] | ||||||||||
Proceeds from loan | $ 77,500 | $ 77,595 | ||||||||
Note payable | 0 | $ 0 | ||||||||
EIDL Loan [Member] | ||||||||||
Debt Instrument [Line Items] | ||||||||||
Debt stated interest rate | 3.75% | |||||||||
Proceeds from loan | $ 150,000 | |||||||||
Note payable | $ 150,000 | $ 150,000 |
CAPITAL STRUCTURE (Details - Op
CAPITAL STRUCTURE (Details - Option activity) - Stock Options [Member] - USD ($) | 2 Months Ended | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2023 | Dec. 31, 2022 | |
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | |||
Options outstanding, shares | 1,457,500 | 1,457,500 | 0 |
Weighted average exercise price, outstanding | $ 2.18 | $ 2.18 | $ 0 |
Options granted, shares | 1,457,500 | ||
Weighted average exercise price, options granted | $ 2.18 | ||
Weighted average contractual life, options granted | 8 years 6 months 10 days | ||
Options forfeited, shares | 0 | ||
Weighted average exercise price, options forfeited | $ 0 | ||
Options exercised, shares | 0 | ||
Weighted average exercise price, options exercised | $ 0 | ||
Weighted average contractual life, options outstanding | 8 years 6 months 10 days | ||
Intrinsic value, options outstanding | $ 0 | $ 0 |
CAPITAL STRUCTURE (Details - _2
CAPITAL STRUCTURE (Details - Option assumptions) - Stock Options [Member] | 3 Months Ended |
Mar. 31, 2023 | |
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | |
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term | 5 years 4 months 17 days |
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate | 79.35% |
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate | 3.66% |
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate | 0% |
CAPITAL STRUCTURE (Details)
CAPITAL STRUCTURE (Details) - shares | Mar. 31, 2023 | Jan. 20, 2023 | Jan. 03, 2023 | Sep. 14, 2022 | Sep. 13, 2022 | Aug. 19, 2022 | Jul. 28, 2022 | Jun. 28, 2022 | Jun. 27, 2022 | Apr. 14, 2022 | Mar. 02, 2022 |
Coral Investment Partners Warrants [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | 1,000,000 | ||||||||||
Coral Investment Partners Warrants [Member] | Exercise price $2.00 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | 500,000 | ||||||||||
Coral Investment Partners Warrants [Member] | Exercise Price $5.00 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | 500,000 | ||||||||||
Coral Investment Partners Warrants Converted [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | 336,869 | ||||||||||
Coral Investment Partners Warrants Converted [Member] | Exercise price $2.00 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | 168,434 | ||||||||||
Coral Investment Partners Warrants Converted [Member] | Exercise Price $5.00 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | 168,434 | ||||||||||
Warrant Holder 1 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | 1,497,500 | ||||||||||
Class of Warrant or Right, Outstanding Gross | 1,500,000 | ||||||||||
Class of Warrant or Right, Outstanding | (2,500) | ||||||||||
Warrant Holder 1 [Member] | Exercise price $2.00 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | 500,000 | ||||||||||
Class of Warrant or Right, Outstanding Gross | 500,000 | ||||||||||
Warrant Holder 1 [Member] | Exercise Price $5.00 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | 500,000 | ||||||||||
Class of Warrant or Right, Outstanding Gross | 500,000 | ||||||||||
Warrant Holder 1 [Member] | Exercise Price $1.00 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | 497,500 | ||||||||||
Class of Warrant or Right, Outstanding Gross | 500,000 | ||||||||||
Class of Warrant or Right, Outstanding | (2,500) | ||||||||||
Coral Investment Partners Warrants Converted 1 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | 504,461 | ||||||||||
Coral Investment Partners Warrants Converted 1 [Member] | Exercise price $2.00 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | 168,434 | ||||||||||
Coral Investment Partners Warrants Converted 1 [Member] | Exercise Price $5.00 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | 168,434 | ||||||||||
Coral Investment Partners Warrants Converted 1 [Member] | Exercise Price $1.00 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | 167,592 | ||||||||||
Warrant Holder 2 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | 100,000 | ||||||||||
Class of Warrant or Right, Outstanding Gross | 400,000 | (25,000) | (270,000) | (5,000) | |||||||
Warrant Holder 2 [Member] | Exercise price $2.00 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding Gross | 100,000 | (25,000) | (75,000) | ||||||||
Warrant Holder 2 [Member] | Exercise Price $5.00 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | 100,000 | ||||||||||
Class of Warrant or Right, Outstanding Gross | 100,000 | ||||||||||
Warrant Holder 2 [Member] | Exercise Price $1.00 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding Gross | 200,000 | (195,000) | (5,000) | ||||||||
Coral Investment Partners Warrants Converted 2 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | 33,687 | ||||||||||
Coral Investment Partners Warrants Converted 2 [Member] | Exercise Price $5.00 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | 33,687 | ||||||||||
Coral Investment Partners Warrants Converted 2 [Member] | Exercise Price $1.00 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | |||||||||||
Purple Bio Tech Warrant [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | 300,000 | ||||||||||
Purple Bio Tech Warrant [Member] | Exercise Price $5.00 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | 300,000 | ||||||||||
Purple Bio Tech Warrant Converted [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | 101,061 | ||||||||||
Warrant Holder 3 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding Gross | 600,000 | (10,000) | (115,000) | ||||||||
Warrant Holder 3 [Member] | Transfer To Warrant Holder 4 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding Gross | (300,000) | ||||||||||
Warrant Holder 3 [Member] | Transfer To Warrant Holder 5 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding Gross | (175,000) | ||||||||||
Warrant Holder 3 [Member] | Exercise Price $1.00 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding Gross | 600,000 | (10,000) | (115,000) | ||||||||
Coral Investment Partners Warrants Converted 3 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | |||||||||||
Coral Investment Partners Warrants Converted 3 [Member] | Exercise Price $1.00 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | |||||||||||
Warrant Holder 4 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding Gross | (300,000) | ||||||||||
Warrant Holder 4 [Member] | Transfer From Warrant Holder 3 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding Gross | 300,000 | ||||||||||
Warrant Holder 4 [Member] | Exercise Price $1.00 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding Gross | (300,000) | ||||||||||
Warrant Holder 4 [Member] | Exercise Price $1.00 [Member] | Transfer From Warrant Holder 3 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding Gross | 300,000 | ||||||||||
Coral Investment Partners Warrants Converted 4 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | |||||||||||
Coral Investment Partners Warrants Converted 4 [Member] | Exercise Price $1.00 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | |||||||||||
Warrant Holder 5 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | 375,000 | ||||||||||
Warrant Holder 5 [Member] | Transfer From Warrant Holder 3 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding Gross | 175,000 | ||||||||||
Warrant Holder 5 [Member] | Transfer From Warrant Holder 9 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding Gross | 200,000 | ||||||||||
Warrant Holder 5 [Member] | Exercise Price $1.00 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | 175,000 | ||||||||||
Warrant Holder 5 [Member] | Exercise Price $1.00 [Member] | Transfer From Warrant Holder 3 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding Gross | 175,000 | ||||||||||
Warrant Holder 5 [Member] | Exercise Price $1.50 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | 200,000 | ||||||||||
Class of Warrant or Right, Outstanding Gross | 200,000 | ||||||||||
Coral Investment Partners Warrants Converted 5 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | 126,326 | ||||||||||
Coral Investment Partners Warrants Converted 5 [Member] | Exercise Price $1.00 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | 58,952 | ||||||||||
Coral Investment Partners Warrants Converted 5 [Member] | Exercise Price $1.50 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | 67,374 | ||||||||||
Warrant Holder 6 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | 250,000 | ||||||||||
Warrant Holder 6 [Member] | Exercise Price $1.50 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | 250,000 | ||||||||||
Coral Investment Partners Warrants Converted 6 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | 84,217 | ||||||||||
Coral Investment Partners Warrants Converted 6 [Member] | Exercise Price $1.50 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | 84,217 | ||||||||||
Warrant Holder 7 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | 400,000 | ||||||||||
Warrant Holder 7 [Member] | Exercise Price $1.50 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | 400,000 | ||||||||||
Coral Investment Partners Warrants Converted 7 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | 134,747 | ||||||||||
Coral Investment Partners Warrants Converted 7 [Member] | Exercise Price $1.50 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | 134,747 | ||||||||||
Warrant Holder 8 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding Gross | 775,000 | (775,000) | |||||||||
Warrant Holder 8 [Member] | Exercise Price $1.50 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding Gross | 775,000 | (775,000) | |||||||||
Coral Investment Partners Warrants Converted 8 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | |||||||||||
Coral Investment Partners Warrants Converted 8 [Member] | Exercise Price $1.50 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | |||||||||||
Warrant Holder 9 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding Gross | 200,000 | ||||||||||
Warrant Holder 9 [Member] | Transfer To Warrant Holder 5 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding Gross | (200,000) | ||||||||||
Warrant Holder 9 [Member] | Exercise Price $1.50 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding Gross | 200,000 | ||||||||||
Warrant Holder 9 [Member] | Exercise Price $1.50 [Member] | Transfer From Warrant Holder 5 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding Gross | (200,000) | ||||||||||
Coral Investment Partners Warrants Converted 9 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | |||||||||||
Coral Investment Partners Warrants Converted 9 [Member] | Exercise Price $1.50 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | |||||||||||
Warrant Holder 10 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding Gross | 350,000 | (246,666) | (50,000) | (53,334) | |||||||
Warrant Holder 10 [Member] | Exercise Price $1.50 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding Gross | 350,000 | (246,666) | (50,000) | (53,334) | |||||||
Coral Investment Partners Warrants Converted 10 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | |||||||||||
Coral Investment Partners Warrants Converted 10 [Member] | Exercise Price $1.50 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | |||||||||||
Warrant Holder 11 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | 470,000 | ||||||||||
Class of Warrant or Right, Outstanding Gross | 300,000 | 170,000 | |||||||||
Warrant Holder 11 [Member] | Exercise price $2.00 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | 150,000 | ||||||||||
Class of Warrant or Right, Outstanding Gross | 150,000 | ||||||||||
Warrant Holder 11 [Member] | Exercise Price $1.00 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | 150,000 | ||||||||||
Class of Warrant or Right, Outstanding Gross | 150,000 | ||||||||||
Warrant Holder 11 [Member] | Exercise Price $1.50 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | 170,000 | ||||||||||
Class of Warrant or Right, Outstanding Gross | 170,000 | ||||||||||
Coral Investment Partners Warrants Converted 11 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | 158,328 | ||||||||||
Coral Investment Partners Warrants Converted 11 [Member] | Exercise price $2.00 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | 50,530 | ||||||||||
Coral Investment Partners Warrants Converted 11 [Member] | Exercise Price $1.00 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | 50,530 | ||||||||||
Coral Investment Partners Warrants Converted 11 [Member] | Exercise Price $1.50 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | 57,268 | ||||||||||
Warrant Holder 12 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding Gross | 1,018,050 | (918,050) | (100,000) | ||||||||
Warrant Holder 12 [Member] | Exercise Price $1.50 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding Gross | 1,018,050 | (918,050) | (100,000) | ||||||||
Coral Investment Partners Warrants Converted 12 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | |||||||||||
Coral Investment Partners Warrants Converted 12 [Member] | Exercise Price $1.50 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | |||||||||||
Warrant Holder 13 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding Gross | 225,000 | (210,000) | (15,000) | ||||||||
Warrant Holder 13 [Member] | Exercise Price $1.50 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding Gross | 225,000 | (210,000) | (15,000) | ||||||||
Coral Investment Partners Warrants Converted 13 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | |||||||||||
Coral Investment Partners Warrants Converted 13 [Member] | Exercise Price $1.50 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | |||||||||||
Warrant Holder 14 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding Gross | 100,000 | (100,000) | |||||||||
Warrant Holder 14 [Member] | Exercise Price $1.00 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding Gross | 100,000 | (100,000) | |||||||||
Coral Investment Partners Warrants Converted 14 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | |||||||||||
Coral Investment Partners Warrants Converted 14 [Member] | Exercise Price $1.50 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | |||||||||||
Warrant Holder 15 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding Gross | 100,000 | (100,000) | |||||||||
Warrant Holder 15 [Member] | Exercise Price $1.50 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding Gross | 100,000 | (100,000) | |||||||||
Coral Investment Partners Warrants Converted 15 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | |||||||||||
Coral Investment Partners Warrants Converted 15 [Member] | Exercise Price $1.50 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | |||||||||||
Warrant Holder 16 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding Gross | 100,000 | (75,000) | (25,000) | ||||||||
Warrant Holder 16 [Member] | Exercise Price $1.50 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding Gross | 100,000 | (75,000) | (25,000) | ||||||||
Coral Investment Partners Warrants Converted 16 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | |||||||||||
Coral Investment Partners Warrants Converted 16 [Member] | Exercise Price $1.50 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | |||||||||||
Warrant Holder 17 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | 250,000 | ||||||||||
Class of Warrant or Right, Outstanding Gross | 52,050 | (52,050) | |||||||||
Warrant Holder 17 [Member] | Exercise Price $1.50 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding Gross | 52,050 | (52,050) | |||||||||
Warrant Holder 17 [Member] | Exercise Price $1.90 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | 250,000 | ||||||||||
Coral Investment Partners Warrants Converted 17 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | |||||||||||
Coral Investment Partners Warrants Converted 17 [Member] | Exercise Price $1.50 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | |||||||||||
Warrant Holder 18 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | 250,000 | ||||||||||
Warrant Holder 18 [Member] | Exercise Price $3.00 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | 250,000 | ||||||||||
Coral Investment Partners Warrants Converted 18 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | 84,217 | ||||||||||
Coral Investment Partners Warrants Converted 18 [Member] | Exercise Price $3.00 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | 84,217 | ||||||||||
Warrant Holder 19 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding Gross | 300,000 | (300,000) | |||||||||
Warrant Holder 19 [Member] | Exercise Price $1.50 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding Gross | 300,000 | (300,000) | |||||||||
Coral Investment Partners Warrants Converted 19 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | |||||||||||
Coral Investment Partners Warrants Converted 19 [Member] | Exercise Price $1.50 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | |||||||||||
Warrant Holder 20 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | 100,000 | ||||||||||
Class of Warrant or Right, Outstanding Gross | 100,000 | ||||||||||
Warrant Holder 20 [Member] | Exercise Price $2.50 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | 100,000 | ||||||||||
Class of Warrant or Right, Outstanding Gross | 100,000 | ||||||||||
Warrant Holder 21 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding Gross | 250,000 | ||||||||||
Warrant Holder 21 [Member] | Exercise Price $1.90 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding Gross | 250,000 | ||||||||||
Warrant [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | 4,992,500 | ||||||||||
Warrant [Member] | Exercise price $2.00 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | 1,150,000 | ||||||||||
Warrant [Member] | Exercise Price $5.00 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | 1,400,000 | ||||||||||
Warrant [Member] | Exercise Price $1.00 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | 822,500 | ||||||||||
Warrant [Member] | Exercise Price $1.50 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | 1,020,000 | ||||||||||
Warrant [Member] | Exercise Price $3.00 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | 250,000 | ||||||||||
Warrant [Member] | Exercise Price $2.50 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | 100,000 | ||||||||||
Warrant [Member] | Exercise Price $1.90 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | 250,000 | ||||||||||
Warrant Converted [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | 1,913,912 | ||||||||||
Warrant Converted [Member] | Exercise price $2.00 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | 387,399 | ||||||||||
Warrant Converted [Member] | Exercise Price $5.00 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | 471,616 | ||||||||||
Warrant Converted [Member] | Exercise Price $1.00 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | 277,074 | ||||||||||
Warrant Converted [Member] | Exercise Price $1.50 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | 343,606 | ||||||||||
Warrant Converted [Member] | Exercise Price $3.00 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | 84,217 | ||||||||||
Warrant Converted [Member] | Exercise Price $2.50 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | 100,000 | ||||||||||
Warrant Converted [Member] | Exercise Price $1.90 [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Class of Warrant or Right, Outstanding | 250,000 |
CAPITAL STRUCTURE (Details Narr
CAPITAL STRUCTURE (Details Narrative) - USD ($) | 1 Months Ended | 3 Months Ended | 12 Months Ended | |||||||||||||||||||||
Feb. 18, 2022 | Feb. 28, 2021 | Mar. 31, 2023 | Mar. 31, 2022 | Dec. 31, 2021 | Jan. 03, 2023 | Dec. 31, 2022 | Sep. 14, 2022 | Sep. 13, 2022 | Sep. 06, 2022 | Aug. 19, 2022 | Jul. 28, 2022 | Jul. 27, 2022 | Jul. 13, 2022 | Jun. 27, 2022 | Apr. 14, 2022 | Mar. 30, 2022 | Mar. 02, 2022 | Jan. 28, 2022 | Dec. 20, 2021 | Sep. 22, 2021 | Jul. 30, 2021 | May 28, 2021 | Nov. 23, 2020 | |
Class of Stock [Line Items] | ||||||||||||||||||||||||
Common Stock, Shares Authorized | 150,000,000 | 150,000,000 | ||||||||||||||||||||||
Common Stock, Par or Stated Value Per Share | $ 0.0001 | $ 0.0001 | ||||||||||||||||||||||
Preferred Stock, Shares Authorized | 10,000,000 | 10,000,000 | ||||||||||||||||||||||
Preferred Stock, Par or Stated Value Per Share | $ 0.0001 | $ 0.0001 | ||||||||||||||||||||||
Common Stock, Shares, Issued | 20,941,036 | 19,566,839 | ||||||||||||||||||||||
Common Stock, Shares, Outstanding | 20,941,036 | 19,566,839 | ||||||||||||||||||||||
Adjustments to Additional Paid in Capital, Other | $ 0 | |||||||||||||||||||||||
Capital distributions | 0 | $ 0 | ||||||||||||||||||||||
Treasury stock | $ 0 | |||||||||||||||||||||||
Preferred Stock, Shares Issued | 0 | 0 | ||||||||||||||||||||||
Preferred Stock, Shares Outstanding | 0 | 0 | ||||||||||||||||||||||
Share-Based Payment Arrangement, Noncash Expense | $ 122,391 | 0 | ||||||||||||||||||||||
Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount | 1,320,050 | |||||||||||||||||||||||
Stock Options [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Share-Based Payment Arrangement, Noncash Expense | $ 122,391 | $ 0 | ||||||||||||||||||||||
Series B Preferred Stock [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Preferred Stock, Shares Issued | 8,000 | |||||||||||||||||||||||
Preferred Stock, Shares Outstanding | 8,000 | |||||||||||||||||||||||
Held By Vinings Shareholders [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Stock Repurchased During Period, Shares | 110,762 | |||||||||||||||||||||||
Stock Repurchased During Period, Value | $ 247,165 | |||||||||||||||||||||||
Treasury Stock, Shares, Retired | 110,762 | |||||||||||||||||||||||
Coral Investment Partners [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 336,869 | 500,000 | ||||||||||||||||||||||
Warrants and Rights Outstanding, Maturity Date | Nov. 30, 2023 | |||||||||||||||||||||||
Coral Investment Partners [Member] | Common Class A [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 2 | |||||||||||||||||||||||
Coral Investment Partners [Member] | Common Class B [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 5 | |||||||||||||||||||||||
Warrant Holder 1 [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 504,461 | |||||||||||||||||||||||
Warrants and Rights Outstanding, Maturity Date | Jun. 01, 2026 | |||||||||||||||||||||||
Warrant Holder 1 [Member] | $1 per share price [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 500,000 | |||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 1 | |||||||||||||||||||||||
Warrants exercised shares | 2,500 | |||||||||||||||||||||||
Warrant Holder 1 [Member] | Per Share 2 [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 500,000 | |||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 2 | |||||||||||||||||||||||
Warrant Holder 1 [Member] | $5 per share price [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 500,000 | |||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 5 | |||||||||||||||||||||||
Warrant Holder 2 [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 33,687 | |||||||||||||||||||||||
Warrants and Rights Outstanding, Maturity Date | Jul. 26, 2026 | |||||||||||||||||||||||
Warrant Holder 2 [Member] | $1 per share price [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 200,000 | |||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 1 | |||||||||||||||||||||||
Warrants exercised shares | 195,000 | 5,000 | ||||||||||||||||||||||
Warrant Holder 2 [Member] | Per Share 2 [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 100,000 | |||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 2 | |||||||||||||||||||||||
Warrants exercised shares | 75,000 | |||||||||||||||||||||||
Warrants expired shares | 25,000 | |||||||||||||||||||||||
Warrant Holder 2 [Member] | $5 per share price [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 100,000 | |||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 5 | |||||||||||||||||||||||
Purple Bio Tech [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 101,061 | 300,000 | ||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 5 | |||||||||||||||||||||||
Purple Bio Tech [Member] | Common Stock Purchase Warrants [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Share-Based Payment Arrangement, Noncash Expense | $ 1,897,585 | |||||||||||||||||||||||
Warrant Holder 3 [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 600,000 | |||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 1 | |||||||||||||||||||||||
Warrants and Rights Outstanding, Maturity Date | Dec. 20, 2026 | |||||||||||||||||||||||
Warrants exercised shares | 115,000 | |||||||||||||||||||||||
Warrants expired shares | 10,000 | |||||||||||||||||||||||
Class of Warrant or Right, Outstanding | 0 | |||||||||||||||||||||||
Warrant Holder 3 [Member] | Transferred To Warrant Holder 4 [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Warrants transferred | 300,000 | |||||||||||||||||||||||
Warrant Holder 3 [Member] | Transferred To Warrant Holder 5 [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Warrants transferred | 175,000 | |||||||||||||||||||||||
Warrant Holder 4 [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 300,000 | |||||||||||||||||||||||
Warrants exercised shares | 300,000 | |||||||||||||||||||||||
Class of Warrant or Right, Outstanding | 0 | |||||||||||||||||||||||
Warrant Holder 5 [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 126,326 | 175,000 | ||||||||||||||||||||||
Warrant Holder 9 [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 200,000 | |||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 1.50 | |||||||||||||||||||||||
Warrants and Rights Outstanding, Maturity Date | Jan. 31, 2024 | |||||||||||||||||||||||
Class of Warrant or Right, Outstanding | 0 | |||||||||||||||||||||||
Warrant Holder 9 [Member] | Transferred To Warrant Holder 5 [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Warrants transferred | 200,000 | |||||||||||||||||||||||
Warrant Holder 6 [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 84,217 | 250,000 | ||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 1.50 | |||||||||||||||||||||||
Warrants and Rights Outstanding, Maturity Date | Jan. 31, 2024 | |||||||||||||||||||||||
Warrant Holder 7 [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 134,747 | 400,000 | ||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 1.50 | |||||||||||||||||||||||
Warrants and Rights Outstanding, Maturity Date | Jan. 31, 2024 | |||||||||||||||||||||||
Warrant Holder 8 [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 775,000 | |||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 1.50 | |||||||||||||||||||||||
Warrants and Rights Outstanding, Maturity Date | Jan. 31, 2024 | |||||||||||||||||||||||
Warrants exercised shares | 775,000 | |||||||||||||||||||||||
Class of Warrant or Right, Outstanding | 0 | |||||||||||||||||||||||
Warrant Holder 10 [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 350,000 | |||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 1.50 | |||||||||||||||||||||||
Warrants and Rights Outstanding, Maturity Date | Jan. 31, 2024 | |||||||||||||||||||||||
Warrants exercised shares | 246,666 | 50,000 | 53,334 | |||||||||||||||||||||
Class of Warrant or Right, Outstanding | 0 | |||||||||||||||||||||||
Warrant Holder 11 [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 158,328 | |||||||||||||||||||||||
Warrants and Rights Outstanding, Maturity Date | Jan. 31, 2024 | |||||||||||||||||||||||
Warrant Holder 11 [Member] | $1 per share price [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 150,000 | |||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 1 | |||||||||||||||||||||||
Warrant Holder 11 [Member] | Per Share 2 [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 150,000 | |||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 2 | |||||||||||||||||||||||
Warrant Holder 11 [Member] | $1.50 per share price [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 170,000 | |||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 1.50 | |||||||||||||||||||||||
Warrants and Rights Outstanding, Maturity Date | Jan. 31, 2024 | |||||||||||||||||||||||
Warrant Holder 12 [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 1,018,050 | |||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 1.50 | |||||||||||||||||||||||
Warrants and Rights Outstanding, Maturity Date | Jan. 31, 2024 | |||||||||||||||||||||||
Warrants exercised shares | 918,050 | 100,000 | ||||||||||||||||||||||
Class of Warrant or Right, Outstanding | 0 | |||||||||||||||||||||||
Warrant Holder 13 [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 225,000 | |||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 1.50 | |||||||||||||||||||||||
Warrants and Rights Outstanding, Maturity Date | Jan. 31, 2024 | |||||||||||||||||||||||
Warrants exercised shares | 210,000 | 15,000 | ||||||||||||||||||||||
Class of Warrant or Right, Outstanding | 0 | |||||||||||||||||||||||
Warrant Holder 14 [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 100,000 | |||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 1 | |||||||||||||||||||||||
Warrants and Rights Outstanding, Maturity Date | Jan. 31, 2024 | |||||||||||||||||||||||
Warrants exercised shares | 100,000 | |||||||||||||||||||||||
Class of Warrant or Right, Outstanding | 0 | |||||||||||||||||||||||
Warrant Holder 15 [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 100,000 | |||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 1.50 | |||||||||||||||||||||||
Warrants and Rights Outstanding, Maturity Date | Jan. 31, 2024 | |||||||||||||||||||||||
Warrants exercised shares | 100,000 | |||||||||||||||||||||||
Class of Warrant or Right, Outstanding | 0 | |||||||||||||||||||||||
Warrant Holder 16 [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 100,000 | |||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 1.50 | |||||||||||||||||||||||
Warrants and Rights Outstanding, Maturity Date | Jan. 31, 2024 | |||||||||||||||||||||||
Warrants exercised shares | 75,000 | 25,000 | ||||||||||||||||||||||
Class of Warrant or Right, Outstanding | 0 | |||||||||||||||||||||||
Warrant Holder 17 [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 52,050 | |||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 1.50 | |||||||||||||||||||||||
Warrants and Rights Outstanding, Maturity Date | Jan. 31, 2024 | |||||||||||||||||||||||
Warrants exercised shares | 52,050 | |||||||||||||||||||||||
Class of Warrant or Right, Outstanding | 0 | |||||||||||||||||||||||
Warrant Holder 18 [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 84,217 | 250,000 | ||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 3 | |||||||||||||||||||||||
Warrants and Rights Outstanding, Maturity Date | Mar. 30, 2024 | |||||||||||||||||||||||
Warrant Holder 19 [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 300,000 | |||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 1.50 | |||||||||||||||||||||||
Warrants and Rights Outstanding, Maturity Date | Apr. 01, 2027 | |||||||||||||||||||||||
Warrants exercised shares | 300,000 | |||||||||||||||||||||||
Class of Warrant or Right, Outstanding | 0 | |||||||||||||||||||||||
Warrant Holder 20 [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 100,000 | |||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 2.50 | |||||||||||||||||||||||
Warrants and Rights Outstanding, Maturity Date | Jan. 02, 2027 | |||||||||||||||||||||||
Warrant Holder 21 [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 250,000 | |||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 1.90 | |||||||||||||||||||||||
Warrants and Rights Outstanding, Maturity Date | Jan. 19, 2027 |
COMMITMENTS AND CONTINGENCIES_2
COMMITMENTS AND CONTINGENCIES (Details) | Mar. 31, 2023 USD ($) |
Commitments and Contingencies Disclosure [Abstract] | |
2023 | $ 33,750 |
2024 | 18,750 |
Total minimum lease payments: | 52,500 |
Less amount representing interest | (6,216) |
Present value of minimum lease payments: | $ 46,284 |
COMMITMENTS AND CONTINGENCIES_3
COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($) | 1 Months Ended | 3 Months Ended | 12 Months Ended | ||||
Aug. 31, 2022 | Mar. 31, 2023 | Mar. 31, 2022 | Dec. 31, 2021 | Jan. 25, 2023 | Dec. 31, 2022 | Jun. 30, 2021 | |
Other Commitments [Line Items] | |||||||
Operating Lease, Expense | $ 11,250 | $ 11,250 | |||||
Operating Lease, Right-of-Use Asset | 49,065 | $ 58,914 | |||||
Operating Lease, Liability, Current | 31,561 | 41,618 | |||||
Operating Lease, Liability, Noncurrent | 14,723 | 14,723 | |||||
Minimum future royalty payments | 0 | 0 | |||||
Other Income | 35 | $ 0 | |||||
Royalty advance | $ 0 | $ 0 | |||||
CAR T License [Member] | |||||||
Other Commitments [Line Items] | |||||||
Initial license fee | $ 75,000 | ||||||
Annual maintenance fee description | annual maintenance fees ranging between $15,000 and $25,000 | ||||||
Milestone payable | $ 716,714 | ||||||
Pharmaceutical Marketing Partner [Member] | |||||||
Other Commitments [Line Items] | |||||||
Deferred Revenue | $ 1,000,000 | ||||||
Other Income | $ 1,000,000 |
401(k) PROFIT-SHARING PLAN (Det
401(k) PROFIT-SHARING PLAN (Details Narrative) - USD ($) | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
Retirement Benefits [Abstract] | ||
Defined Benefit Plan, Plan Assets, Contributions by Employer | $ 0 | $ 0 |
INCOME TAXES (Details Narrative
INCOME TAXES (Details Narrative) - USD ($) | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
Income Tax Disclosure [Abstract] | ||
Income tax expense or benefit | $ 0 | $ 0 |